TH MEDICAL-B

TH MEDICAL-B staged a sharp recovery after a deep early-morning gap-down, driven by the acceleration of AI surgical robot commercialization and profit-taking following a recent 52-week high. The stock oscillated 13.8% intraday (low HK$769, high HK$875), closing +5.77% at HK$852.5. Q4 revenue surged 642% YoY to HK$6.67M, net loss narrowed 10% YoY, but net margin remained deeply negative at -278%. The stock has rebounded 166% from its 52-week low of HK$320, standing above both the MA20 (HK$640) and MA60 (HK$572), with a YTD gain of 113%. However, a PB of 114.6x raises concerns about valuation sustainability.

2697.HK opened higher and rallied in the morning session, climbing from HKD 736.0 to an intraday high of HKD 770.0 and closing at HKD 761.5, up 3.47% from the previous close of HKD 736.0. The surge was primarily driven by positive market sentiment around the accelerated commercialization of AI surgical robots, with multiple recent reports highlighting the prospects of its percutaneous puncture surgical robots. However, fundamental pressures persist: Q4 2025 EPS was -HKD 0.5776, net loss of HKD 18.56 million, revenue grew 642% YoY but only to HKD 6.67 million, net profit margin was -278%, PB stands at 102.34x, PE at -272.08x. The stock is 11.45% below its 52-week high of HKD 860, but well above its MA20 of HKD 631.3 and MA60 of HKD 561.6, with YTD gains of 90.38%.

TH MEDICAL-B opened lower and continued to decline in the morning session, closing down 6.6% (from HK$732.5 to HK$683.0) with an intraday range of HK$700.0 to HK$732.5. The drop was primarily driven by profit-taking after the recent hype around AI surgical robot commercialization, as the stock saw four declines in the last five trading sessions, shedding over 19% cumulatively. Despite Q4 2025 revenue surging 642% YoY to HK$6.67 million, the company still posted a net loss of HK$18.56 million with a net profit margin of -278%, keeping profitability concerns in focus. The stock is now 20.58% below its 52-week high of HK$860 (Aug 5) but retains a 70.75% YTD gain, with both MA20 (HK$622.6) and MA60 (HK$553.2) below the current price, indicating a relatively strong technical posture. However, the PB ratio of 91.79x and negative PE suggest limited fundamental support for valuation.

TH MEDICAL-B opened sharply lower in the morning session, with the stock declining 5.56% to close at HK$655, down from the previous close of HK$693.5. The recent enthusiasm over accelerated commercialization of AI surgical robots has been overshadowed by persistent profit concerns, as the company continues to report net losses. The stock opened at HK$720 and quickly fell to an intraday low of HK$655, near the session's bottom, with a total decline of 5.56% in the morning. The current price of HK$655 has fallen below the 20-day moving average of HK$613.66, though it remains up 63.75% year-to-date and 23.84% below the 52-week high of HK$860. Q4 2025 operating revenue surged 642.09% YoY to HK$6.67 million, but net loss remained at HK$18.56 million, with a net profit margin of -278.04%, highlighting ongoing profitability challenges. However, the stock's PB of 88.03x continues to reflect elevated valuation expectations.

TH MEDICAL-B opened lower and continued its descent in the morning session, spiraling down to an intraday low of HK$693, down 5.07% from the prior close, with a meager turnover of just 4,720 shares and a turnover rate of 0.01%. The stock had recently rallied sharply, hitting a 52-week high of HK$860 before retreating 19.42% from that peak, yet still boasting a YTD gain of 73.25%. While AI surgical robot commercialization has been a positive catalyst, the company's fundamentals remain under pressure—Q4 2025 revenue was only HK$6.67 million, up 642% YoY, but net loss stood at HK$18.56 million, with EPS of -HK$0.58, net margin of -278%, and a PB of 93.1x. Though the day's decline has already reached the intraday low, the current price of HK$693 sits below the MA20 of HK$604.8 and MA60 of HK$542.2, suggesting potential for a technical rebound.